Cargando…
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Obesity is a complex disease characterized by excessive fat accumulation which is caused by genetic, environmental and other factors. In recent years, there has been an increase in the morbidity, disability rate,and mortality due to obesity, making it great threat to people’s health and lives, and i...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945324/ https://www.ncbi.nlm.nih.gov/pubmed/36843578 http://dx.doi.org/10.3389/fendo.2023.1085799 |
_version_ | 1784892117863104512 |
---|---|
author | Wang, Jing-Yue Wang, Quan-Wei Yang, Xin-Yu Yang, Wei Li, Dong-Rui Jin, Jing-Yu Zhang, Hui-Cong Zhang, Xian-Feng |
author_facet | Wang, Jing-Yue Wang, Quan-Wei Yang, Xin-Yu Yang, Wei Li, Dong-Rui Jin, Jing-Yu Zhang, Hui-Cong Zhang, Xian-Feng |
author_sort | Wang, Jing-Yue |
collection | PubMed |
description | Obesity is a complex disease characterized by excessive fat accumulation which is caused by genetic, environmental and other factors. In recent years, there has been an increase in the morbidity, disability rate,and mortality due to obesity, making it great threat to people’s health and lives, and increasing public health care expenses. Evidence from previous studies show that weight loss can significantly reduce the risk of obesity-related complications and chronic diseases. Diet control, moderate exercise, behavior modification programs, bariatric surgery and prescription drug treatment are the major interventions used to help people lose weight. Among them, anti-obesity drugs have high compliance rates and cause noticeable short-term effects in reducing obese levels. However, given the safety or effectiveness concerns of anti-obesity drugs, many of the currently used drugs have limited clinical use. Glucagon-like peptide-1 receptor (GLP-1R) agonists are a group of drugs that targets incretin hormone action, and its receptors are widely distributed in nerves, islets, heart, lung, skin, and other organs. Several animal experiments and clinical trials have demonstrated that GLP-1R agonists are more effective in treating or preventing obesity. Therefore, GLP-1R agonists are promising agents for the treatment of obese individuals. This review describes evidence from previous research on the effects of GLP-1R agonists on obesity. We anticipate that this review will generate data that will help biomedical researchers or clinical workers develop obesity treatments based on GLP-1R agonists. |
format | Online Article Text |
id | pubmed-9945324 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99453242023-02-23 GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach Wang, Jing-Yue Wang, Quan-Wei Yang, Xin-Yu Yang, Wei Li, Dong-Rui Jin, Jing-Yu Zhang, Hui-Cong Zhang, Xian-Feng Front Endocrinol (Lausanne) Endocrinology Obesity is a complex disease characterized by excessive fat accumulation which is caused by genetic, environmental and other factors. In recent years, there has been an increase in the morbidity, disability rate,and mortality due to obesity, making it great threat to people’s health and lives, and increasing public health care expenses. Evidence from previous studies show that weight loss can significantly reduce the risk of obesity-related complications and chronic diseases. Diet control, moderate exercise, behavior modification programs, bariatric surgery and prescription drug treatment are the major interventions used to help people lose weight. Among them, anti-obesity drugs have high compliance rates and cause noticeable short-term effects in reducing obese levels. However, given the safety or effectiveness concerns of anti-obesity drugs, many of the currently used drugs have limited clinical use. Glucagon-like peptide-1 receptor (GLP-1R) agonists are a group of drugs that targets incretin hormone action, and its receptors are widely distributed in nerves, islets, heart, lung, skin, and other organs. Several animal experiments and clinical trials have demonstrated that GLP-1R agonists are more effective in treating or preventing obesity. Therefore, GLP-1R agonists are promising agents for the treatment of obese individuals. This review describes evidence from previous research on the effects of GLP-1R agonists on obesity. We anticipate that this review will generate data that will help biomedical researchers or clinical workers develop obesity treatments based on GLP-1R agonists. Frontiers Media S.A. 2023-02-01 /pmc/articles/PMC9945324/ /pubmed/36843578 http://dx.doi.org/10.3389/fendo.2023.1085799 Text en Copyright © 2023 Wang, Wang, Yang, Yang, Li, Jin, Zhang and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Wang, Jing-Yue Wang, Quan-Wei Yang, Xin-Yu Yang, Wei Li, Dong-Rui Jin, Jing-Yu Zhang, Hui-Cong Zhang, Xian-Feng GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach |
title | GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach |
title_full | GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach |
title_fullStr | GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach |
title_full_unstemmed | GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach |
title_short | GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach |
title_sort | glp−1 receptor agonists for the treatment of obesity: role as a promising approach |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945324/ https://www.ncbi.nlm.nih.gov/pubmed/36843578 http://dx.doi.org/10.3389/fendo.2023.1085799 |
work_keys_str_mv | AT wangjingyue glp1receptoragonistsforthetreatmentofobesityroleasapromisingapproach AT wangquanwei glp1receptoragonistsforthetreatmentofobesityroleasapromisingapproach AT yangxinyu glp1receptoragonistsforthetreatmentofobesityroleasapromisingapproach AT yangwei glp1receptoragonistsforthetreatmentofobesityroleasapromisingapproach AT lidongrui glp1receptoragonistsforthetreatmentofobesityroleasapromisingapproach AT jinjingyu glp1receptoragonistsforthetreatmentofobesityroleasapromisingapproach AT zhanghuicong glp1receptoragonistsforthetreatmentofobesityroleasapromisingapproach AT zhangxianfeng glp1receptoragonistsforthetreatmentofobesityroleasapromisingapproach |